Follow
Sean Wei Xiang Ong
Sean Wei Xiang Ong
University of Toronto; University of Melbourne; National Centre for Infectious Diseases
Verified email at mail.utoronto.ca
Title
Cited by
Cited by
Year
Remdesivir for the treatment of Covid-19—preliminary report
JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ...
New England Journal of Medicine 383 (19), 1813-1836, 2020
65042020
Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient
SWX Ong, YK Tan, PY Chia, TH Lee, OT Ng, MSY Wong, K Marimuthu
Jama 323 (16), 1610-1612, 2020
27002020
Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore
BE Young, SWX Ong, S Kalimuddin, JG Low, SY Tan, J Loh, OT Ng, ...
Jama 323 (15), 1488-1494, 2020
23492020
Remdesivir for 5 or 10 days in patients with severe Covid-19
JD Goldman, DCB Lye, DS Hui, KM Marks, R Bruno, R Montejano, ...
New England Journal of Medicine 383 (19), 1827-1837, 2020
13302020
Baricitinib plus remdesivir for hospitalized adults with Covid-19
AC Kalil, TF Patterson, AK Mehta, KM Tomashek, CR Wolfe, V Ghazaryan, ...
New England Journal of Medicine 384 (9), 795-807, 2021
12662021
Detection of air and surface contamination by SARS-CoV-2 in hospital rooms of infected patients
PY Chia, KK Coleman, YK Tan, SWX Ong, M Gum, SK Lau, XF Lim, ...
Nature communications 11 (1), 1-7, 2020
803*2020
Clinical and virological features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern: a retrospective cohort study comparing B. 1.1. 7 (Alpha …
SWX Ong, CJ Chiew, LW Ang, TM Mak, L Cui, MPHS Toh, YD Lim, ...
Clinical Infectious Diseases 75 (1), e1128-e1136, 2022
320*2022
Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study
PY Chia, SWX Ong, CJ Chiew, LW Ang, JM Chavatte, TM Mak, L Cui, ...
Clinical microbiology and infection 28 (4), 612. e1-612. e7, 2022
2872022
Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study
WN Chia, F Zhu, SWX Ong, BE Young, SW Fong, N Le Bert, CW Tan, ...
The Lancet Microbe 2 (6), e240-e249, 2021
2692021
A neutralizing monoclonal antibody for hospitalized patients with Covid-19
ACTIV-3/TICO LY-CoV555 Study Group
New England Journal of Medicine 384 (10), 905-914, 2021
2532021
Viral dynamics and immune correlates of coronavirus disease 2019 (COVID-19) severity
BE Young, SWX Ong, LFP Ng, DE Anderson, WN Chia, PY Chia, LW Ang, ...
Clinical Infectious Diseases 73 (9), e2932-e2942, 2021
1502021
Viral load of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in respiratory aerosols emitted by patients with coronavirus disease 2019 (COVID-19) while breathing …
KK Coleman, DJW Tay, KS Tan, SWX Ong, TS Than, MH Koh, YQ Chin, ...
Clinical Infectious Diseases 74 (10), 1722-1728, 2022
130*2022
Absence of contamination of personal protective equipment (PPE) by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
SWX Ong, YK Tan, S Sutjipto, PY Chia, BE Young, M Gum, SK Lau, ...
Infection Control & Hospital Epidemiology 41 (5), 614-616, 2020
782020
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial
AC Kalil, AK Mehta, TF Patterson, N Erdmann, CA Gomez, MK Jain, ...
The lancet respiratory medicine 9 (12), 1365-1376, 2021
702021
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised …
WH Self, U Sandkovsky, CS Reilly, DM Vock, RL Gottlieb, M Mack, ...
The Lancet Infectious Diseases 22 (5), 622-635, 2022
622022
Association of higher body mass index with severe coronavirus disease 2019 (COVID-19) in younger patients
SWX Ong, BE Young, YS Leo, DC Lye
Clinical Infectious Diseases 71 (16), 2300-2302, 2020
572020
Diabetes and overweight/obesity are independent, nonadditive risk factors for in-hospital severity of COVID-19: an international, multicenter retrospective meta-analysis
DK Longmore, JE Miller, S Bekkering, C Saner, E Mifsud, Y Zhu, R Saffery, ...
Diabetes Care 44 (6), 1281-1290, 2021
492021
Persistent symptoms and association with inflammatory cytokine signatures in recovered coronavirus disease 2019 patients
SWX Ong, SW Fong, BE Young, YH Chan, B Lee, SN Amrun, RSL Chee, ...
Open forum infectious diseases 8 (6), ofab156, 2021
472021
Associations of viral ribonucleic acid (RNA) shedding patterns with clinical illness and immune responses in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) infection
PH Lee, WC Tay, S Sutjipto, SW Fong, SWX Ong, WE Wei, YH Chan, ...
Clinical & translational immunology 9 (7), e1160, 2020
342020
Responses to a neutralizing monoclonal antibody for hospitalized patients with COVID-19 according to baseline antibody and antigen levels: a randomized controlled trial
ACTIV-3/TICO Bamlanivimab Study Group*
Annals of internal medicine 175 (2), 234-243, 2022
312022
The system can't perform the operation now. Try again later.
Articles 1–20